Norway Biologics Market Size & Outlook, 2026-2033

Name: Norway Biologics Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The biologics market in Norway is expected to reach a projected revenue of US$ 3,265.4 million by 2033. A compound annual growth rate of 9.4% is expected of Norway biologics market from 2026 to 2033.

Norway biologics source outlook (Revenue, USD million, 2021-2033)
- Microbial
- Mammalian
- Others
Norway biologics product outlook (Revenue, USD million, 2021-2033)
- Monoclonal antibodies (MABs)
  - Therapeutic
    - Direct MAB Agents
    - Targeting MAB Agents
  - Diagnostics
    - Biochemical Analysis
    - Diagnostic Imaging
  - Protein Purification
  - Others
- Vaccines
- Recombinant Proteins
- Antisense & RNAi Therapeutics
- Others
Norway biologics disease category outlook (Revenue, USD million, 2021-2033)
- Oncology
  - Monoclonal antibodies (MABs)
  - Vaccines
  - Recombinant Proteins
  - Antisense & RNAi Therapeutics
  - Others
- Infectious Diseases
  - Vaccines
  - MABs
  - Antisense & RNAi Therapeutics
  - Recombinant Proteins
  - Others
- Immunological Disorders
- Cardiovascular Disorders
- Haematological Disorders
- Others
Norway biologics manufacturing outlook (Revenue, USD million, 2021-2033)
- In-house
- Outsourced

Norway Biologics Market Size & Outlook, 2026-2033

Sign up - it's easy, and free!